glp-1 chronic kidney disease Design and discovery of a highly potent ultralong-acting and glucagon co-agonist for attenuating renal fibrosis GLP1 Receptor Agonists vs SGLT2-I

Figure 3: Head-to-head efficacy comparison restricted to Standard-design, Non-T2D trials

"In the future, we may have more data on lower doses

Mieyal, J.J., Gallogly, M.M., Qanungo, S., Sabens, E.A

A person at a normal BMI can still have insulin resistance, impaired glucose tolerance, or elevated inflammationconditions that accelerate aging and disease risk

There are 20 amino acids that make up the estimated 2 million different types of proteins

Other large drugmakers such as Pfizer which has a widely followed but so far ill-fated weight loss drug program Amgen, Roche and AstraZeneca also outlined their strategies for joining the market